Stock Analysis
Alumis Inc. (ALMS) Stock Analysis
Alumis Inc. (ALMS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Alumis Inc. (ALMS) currently has an AIQ Score of 20/100, indicating a very bearish setup. Quality is the strongest factor at 29/100. Momentum is the weakest current factor at 13/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ALMS at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $5.60 |
| AIQ Score | 20/100 |
| Overall View | Very Bearish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $724.05M |
| P/E Ratio (TTM) | -1.61 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.73 |
| Revenue (Q3 FY2026) | $1.91M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.98 |
| Volume | 1.49M |
| 52-week range | $4.60-$31.35 |
| RSI 14 | 34.04 |
| 50-Day SMA | $7.24 |
| 200-Day SMA | $20.44 |
| Analyst Price Target | $26.60 |
| Next Earnings | — |
ALMSAlumis Inc.
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum13
- Value—
- Quality29
- Risk resilience20
- Sentiment—
ALMS Stock Analysis Summary
Alumis Inc. (ALMS) currently has an AIQ Score of 20/100, indicating a very bearish setup. Quality is the strongest factor at 29/100. Momentum is the weakest current factor at 13/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a very bearish regime, ALMS has AIQ Score of 20/100 with Quality base of 29/100 and fading Momentum at 13/100. Wait for component alignment before adding exposure.
Healthcare · -8.65% stock move · ALMS classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ALMS Bullish or Bearish Right Now?
ALMS currently has a very bearish overall setup. Quality is the strongest factor at 29/100, while Momentum is weakest at 13/100. The current evidence suggests a bearish setup.
- - Analyst target implies +375.00% upside from the latest quote.
- - Momentum is weak at 13/100.
- - Risk Resilience is weak at 20/100.
- - Price is -72.60% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (35 vs 6).
Current Consensus
ALMS's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 5 neutral, and 35 sell votes. ALMS's 14-day RSI is 34.04, which places the stock in a weaker momentum range. ALMS's beta is 1.98, indicating greater market sensitivity than the broad market.
What Changed in ALMS?
The largest recent change in ALMS is AIQ Score moving down by 1.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the ALMS Outlook?
The current very bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ALMS Decision Framework
Public evidence layers, setup checks, and risk context for Alumis Inc..
Alumis Inc. (ALMS) Stock Analysis
Alumis Inc. has an AIQ Score of 20/100 in a Very Bearish regime. Quality is strongest at 29/100. Beta is 1.98, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ALMS is in a Very Bearish AIQ regime with score 20/100. |
| Signal Conflict | The primary conflict is that quality leads at 29/100 while momentum lags at 13/100. |
| Factor Evidence | Momentum 13/100 · Quality 29/100 · Risk 20/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 29/100.
Momentum is 13/100 and RSI (14) is 34.0.
ALMS is in a Very Bearish regime at 20/100.
Risk factor is 20/100 with beta 1.98 and annual volatility 137.6%.
Current conflict: quality leads at 29/100 while momentum lags at 13/100.
ALMS Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ALMS Fundamentals
ALMS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ALMS Technical Analysis
ALMS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ALMS Stock Catalysts
Track ALMS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ALMS Dividend Analysis
ALMS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ALMS Financial Data
ALMS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ALMS Risk Analysis
ALMS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ALMS Stock News
ALMS stock news, market tone, recent headlines, and catalyst context.
ALMS vs Biotechnology Peers
Current peer cohort: ALMS · AMLX · ANAB · ARGX · ARQT. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ALMS Current stock | 20/100 | — | 13/100 | 20/100 | 0.65 | 137.60% | Current |
| AMLX Amylyx Pharmaceuticals, Inc. | 78/100 | — | 90/100 | 48/100 | 1.35 | 87.03% | ALMS vs AMLX |
| ANAB AnaptysBio, Inc. | 56/100 | 74/100 | 36/100 | 46/100 | 0.78 | 64.84% | ALMS vs ANAB |
| ARGX argenx SE | 74/100 | 70/100 | 74/100 | 70/100 | 0.28 | 37.87% | ALMS vs ARGX |
| ARQT Arcutis Biotherapeutics, Inc. | 69/100 | 65/100 | 76/100 | 46/100 | 0.59 | 56.50% | ALMS vs ARQT |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for ALMS: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ALMS
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ALMS
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ALMS Stock FAQ
What is ALMS stock price today?
Alumis Inc.'s current stock price is $5.60. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ALMS bullish or bearish right now?
ALMS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ALMS's market cap?
ALMS's market cap is $724.05M based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ALMS's current P/E ratio?
ALMS's current P/E ratio is -1.61 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ALMS's RSI?
ALMS's 14-day RSI is 34.04 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ALMS above its 50-day and 200-day moving averages?
ALMS is -22.69% from its 50-day SMA and -72.60% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ALMS's next earnings date?
ALMS's next earnings date is a key event to check before making a decision. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ALMS pay a dividend?
ALMS's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.